The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


100 milligram(s) Capsule, soft

Boehringer Ingelheim International GmbHEU/1/14/979/001-002

Main Information

Trade NameOfev
Active SubstancesNintedanib
Strength100 milligram(s)
Dosage FormCapsule, soft
Licence HolderBoehringer Ingelheim International GmbH
Licence NumberEU/1/14/979/001-002

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE31 Protein kinase inhibitors


Licence Issued15/01/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back